Figure 5.

The MXP@OC vaccine enhances lymphatic drainage and DC‐mediated immune responses. A) FITC⁺ cells in pLNs and iLNs after the administration of PBS, OC, or MXP@OC. Blue, nuclei; green, OVA‐FITC. B) Schematic illustration of the experimental schedule used to evaluate the immune responses to the nanovaccines. C) OVA‐specific immunoglobulin (IgG) production in the harvested serum. D) Ratios of CD11c⁺SIINFEKL‐H‐2Kb⁺ cells in LNs as measured by FCM. E) Statistical analysis of CD11c⁺SIINFEKL‐H‐2Kb⁺ cells. F,G) Representative FCM plots and statistical analysis of CD11c⁺ CD80⁺ cells. H,I) Representative FCM plots and statistical analysis of CD11c⁺ CD86⁺ cells. J) Representative FCM images of CD3⁺CD8⁺IFN‐γ ⁺ T cells in the splenocytes of immunized mice after restimulation with the SIINFEKL peptide. The data are presented as the means ± SD (n = 5/group). For statistical significance, **P < 0.01, ***P < 0.001, and ****P < 0.0001.